Discover the leading gene therapy companies in the United States, an innovative sector revolutionizing the treatment of genetic diseases. This list explores prominent companies recognized for their research, development, and approval of gene therapies. Learn about the key players driving significant advancements in personalized medicine and the future of biotechnology. Explore companies with the highest market capitalization and those with FDA-approved therapies.
Committed to delivering one-time curative genetic therapies
(+4)
Prime Medicine is a leading gene therapy company due to its innovative Prime Editing technology, which precisely corrects a wide range of genetic mutations. Its "search and replace" approach to DNA sequences offers significant potential for treating previously intractable debilitating diseases.
Innovative medicines company
(+4)
Novartis has demonstrated a significant commitment to gene therapy, developing and commercializing treatments for rare and life-threatening diseases. Its partnership with the University of Pennsylvania led to the first approved CAR-T cell therapy, and it has received FDA approval for gene therapies addressing rare muscle disorders and genetic conditions in children.
Successfully commercialized a gene therapy for a genetic disease in the U.S.
(+3)
Spark Therapeutics has been instrumental in advancing gene therapies, achieving FDA approval for innovative treatments addressing rare genetic diseases. Its focus on inherited retinal diseases and neurodegenerative disorders demonstrates a commitment to transforming healthcare through genetics.
Develops gene therapies for severe genetic disorders
(+4)
Bluebird Bio specializes in developing transformative gene therapies for severe genetic disorders, offering solutions where treatment options are limited. Its focus on researching and delivering curative treatments for conditions like sickle cell disease and β-thalassemia demonstrates a significant impact on medicine. The company, now Genetix Biotherapeutics, maintains its commitment to innovation in the field of gene therapy.
Ranked on Forbes' 2017 list of "World's Most Innovative Companies"
(+4)
BioMarin Pharmaceutical is a leading global biotechnology company dedicated to delivering medicines for people living with genetically defined conditions. Its focus on genetic discovery and the development of gene therapies for rare diseases demonstrates a significant commitment to innovation in this field. The company has a strong track record in researching and developing treatments, including enzyme replacement therapies and new modalities for genetic conditions.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Pioneering a new era of medicines
(+4)
CRISPR Therapeutics has been instrumental in applying CRISPR/Cas9 gene editing technology to develop groundbreaking therapies. The company is responsible for the first-ever approved CRISPR-based therapy, CASGEVY™, showcasing its leadership in translating genetic research into clinical treatments.
Developing novel, potentially curative therapeutics
(+4)
Intellia Therapeutics pioneers the application of CRISPR/Cas9 technology to develop gene therapies that address the root causes of severe diseases. Its focus on both in vivo and ex vivo programs, including an in vivo CRISPR gene editing candidate that has shown Phase 3 readouts, demonstrates its leadership in transforming medicine.
Leading gene editing company
(+4)
Editas Medicine is a pioneering company in CRISPR gene editing, developing medicines for serious diseases using CRISPR/Cas9 and CRISPR/Cas12a systems. Its focus on innovative therapies, such as EDIT-301 for rare diseases and LDLR gene editing for high cholesterol, demonstrates its leadership in the field. The company is advancing the translation of genome editing's potential into clinical treatments, including for the nervous system and neurological diseases.
Focused on precision genetic medicines
(+4)
Sarepta Therapeutics is a leading company in the development of precision genetic medicines for rare diseases, with a particular focus on gene therapy and neuromuscular conditions. Its work has resulted in the approval of groundbreaking therapies, such as Elevidys for Duchenne muscular dystrophy, demonstrating its ability to transform the treatment of devastating conditions.
Strong pipeline across Virology, Oncology and Inflammation
(+4)
Gilead Sciences is a leading biopharmaceutical company in the research and development of antiviral therapies, including significant advancements in HIV and viral hepatitis treatment. Its commitment to innovation extends to expanding its manufacturing and development capabilities to create next-generation therapies, demonstrating its crucial role in advancing medicine. The company is actively involved in pandemic preparedness and the pursuit of cures for emerging and neglected viruses.
Building a new gene therapy manufacturing facility
(+4)
Biogen is dedicated to addressing challenging diseases by leveraging cutting-edge science and driving an innovative pipeline of potential breakthrough therapies. Its research focuses on potentially transformative treatments in neurology, immunology, and rare diseases, including the potential repair of damage caused by multiple sclerosis.
Leading clinical-stage gene therapy company
(+4)
AskBio is a leading clinical-stage gene therapy company, recognized for its advanced technology platform, which includes Pro10™ and an extensive capsid library. Its scientists have pioneered the development of gene therapies for neuromuscular, cardiovascular, and central nervous system disorders, such as muscular dystrophy and congestive heart failure.
Focused on changing treatment for severe genetic diseases
(+4)
Orchard Therapeutics is a prominent company in the gene therapy field, focusing on developing treatments for severe genetic diseases. Its portfolio of hematopoietic stem cell gene therapies has demonstrated sustained clinical benefits in numerous patients, offering innovative solutions for rare conditions.
Focused on core therapeutic areas
(+3)
Bristol Myers Squibb is a leader in cell therapy, with two approved CAR T treatments for distinct targets, redefining possibilities for patients with hematological cancers. The company has strengthened its cell therapy portfolio through strategic acquisitions and collaborations, including the acquisition of Orbital Therapeutics and agreements to develop reagents for ex vivo T-cell therapies.
This ranking is compiled through a comprehensive analysis of gene therapy companies based in the United States, focusing on their impact and leadership within the sector. Our goal is to provide a clear overview of the key players driving innovation in this crucial field.